prasugrel / Generic mfg. - LARVOL DELTA

Economic evaluation of the impact of generic Prasugrel widespread adoption at a national level. (PubMed, Rev Port Cardiol) - No abstract available

HEOR • Journal

PolyACS: A Polypill for Acute Coronary Syndrome (clinicaltrials.gov) - P3 | N=1000 | Not yet recruiting | Sponsor: University of Texas Southwestern Medical Center

New P3 trial • Acute Coronary Syndrome • Cardiovascular

Oral P2Y12 Inhibitors: Victims or Perpetrators? A Focused Review on Pharmacokinetic, Clinically Relevant Drug Interactions. (PubMed, Eur Cardiol) - "The authors critically review pharmacokinetic-related clinically relevant DDIs involving oral P2Y12 inhibitors, focusing on underlying mechanisms, which may reduce safety and effectiveness. Based on significant differences in pharmacokinetic and biotransformation, clopidogrel and ticagrelor are exposed to clinically relevant DDIs as victim or perpetrator drugs, while prasugrel is less susceptible to DDIs."

Journal • PK/PD data • Review • Cardiovascular

Endovascular treatment of posterior circulation aneurysms with flow diverters with hydrophilic polymer coating in patients receiving prasugrel single antiplatelet therapy: a multicenter case series presenting complication and occlusion rates. (PubMed, J Neurointerv Surg) - "In this single-arm retrospective study, HPC-coated FDs with prasugrel SAPT were associated with high safety in the treatment of ruptured and unruptured PCA and high occlusion rates at early- and mid-term FU."

Journal • Cardiovascular • Hematological Disorders • Subarachnoid Hemorrhage

Long-term outcomes of prasugrel-based de-escalation versus conventional therapy after PCI in ACS patients (ESC-WCC 2025) - No abstract available

Clinical • Acute Coronary Syndrome • Cardiovascular

Predicting individualized treatment effects of prasugrel vs ticagrelor for acute coronary syndrome: a post hoc analysis of a randomized clinical trial (ESC-WCC 2025) - No abstract available

Clinical • Retrospective data • Acute Coronary Syndrome • Cardiovascular

Comparative effectiveness of prasugrel and ticagrelor among patients undergoing contemporary PCI: insights from the BMC2 registry (ESC-WCC 2025) - No abstract available

Clinical • HEOR • Acute Coronary Syndrome • Cardiovascular

Effect of Alternative Administrations on P2Y12 Receptor Inhibitors' Pharmacokinetics and Pharmacodynamics: Systematic Review and Meta-Analysis. (PubMed, AAPS J) - "This study aimed to evaluate the impact of these alternative strategies on the pharmacokinetics and pharmacodynamics of clopidogrel, ticagrelor, and prasugrel. No differences were found between prasugrel and ticagrelor or between crushed and chewed tablets in the pharmacodynamic outcomes, providing flexibility in clinical practice. Further research is needed to confirm the clinical relevance of these findings."

Clinical • Journal • PK/PD data • Retrospective data • Review

Bleeding risk assessment tools in acute myocardial infarction: a comparative review and clinical implications. (PubMed, Expert Rev Cardiovasc Ther) - "Future research should focus on AI-driven dynamic risk models, broader validation across diverse populations, and integrating bleeding and ischemic risk stratification into a unified framework. Embedding these tools into electronic health records (EHRs) will enhance clinical decision-making and improve patient outcomes."

Journal • Review • Cardiovascular • Myocardial Infarction

Dual Antiplatelet Therapy Escalation From Standard-dose Clopidogrel to Low-Dose Prasugrel in Patients With High Bleeding and Ischemic Risk Undergoing PCI: A Prospective, Randomized Pharmacodynamic Study (TAILOR-BLEED-2) (clinicaltrials.gov) - P4 | N=40 | Not yet recruiting | Sponsor: University of Florida

New P4 trial • Cardiovascular • Coronary Artery Disease

How to assess P2Y12-antagonist pharmacodynamics? Are the defined assay thresholds optimal? (ISTH 2025) - "Results We analyzed 3628 samples from 2765 patients (55±16 years, 52% women) receiving P2Y12-antagonist single therapy (900 samples: 681 clopidogrel, 98 prasugrel, 28 ticagrelor, 93 cangrelor) or associated with aspirin (2728 samples: 2253, 130, 272, 73, respectively). Results varied depending on the antiplatelet therapy. Table or Figure Upload"

PK/PD data

Allopurinol associated cardiovascular risk and protective effect of colchicine in gout patients: a Dutch nationwide pharmaco-epidemiologic cohort study. (EULAR 2025) - "A CV event was defined as a new dispensed prescription for a platelet aggregation inhibitor (clopidogrel, prasugrel, ticagrelor or dipyridamole). After allopurinol start – especially the first 30 to 90 days - there is a dose-dependent increase in the risk of cardiovascular risk, which is fully countered by concomitant colchicine use. Discontinuation of allopurinol does not lead to a relevant increase in cardiovascular event risk. Concomitant use of colchicine or slower dose escalation of allopurinol seems prudent to decrease the risk of CV events in gout patients starting allopurinol."

Clinical • Cardiovascular • Coronary Artery Disease • Diabetes • Dyslipidemia • Gout • Heart Failure • Hypertension • Inflammatory Arthritis • Rheumatology

Antithrombotic Therapy in Acute Coronary Syndrome Patients with End-Stage Renal Disease: Navigating Efficacy and Safety. (PubMed, J Clin Med) - "The efficacy and safety of various antiplatelet therapies, including aspirin and P2Y12 inhibitors, are evaluated in this population. While potent P2Y12 inhibitors such as ticagrelor and prasugrel have demonstrated potential in reducing ischemic events, they are associated with an increased bleeding risk. The optimal duration of anti-platelet therapy (DAPT) in ESRD patients remains controversial, with studies suggesting potential benefits of prolonged DAPT but also increased bleeding risk. This review underscores the necessity for further research and patient inclusion in clinical trials to establish evidence-based guidelines for tailoring antithrombotic therapy in this high-risk population."

Journal • Review • Acute Coronary Syndrome • Cardiovascular • Chronic Kidney Disease • Nephrology • Renal Disease

ACS-2: The Elderly ACS II Trial (clinicaltrials.gov) - P4 | N=2000 | Completed | Sponsor: Azienda USL Reggio Emilia - IRCCS | Unknown status ➔ Completed

Trial completion • Acute Coronary Syndrome • Atherosclerosis • Cardiovascular • Coronary Artery Disease • Myocardial Ischemia

An Aspirin-Free Strategy for Patients Undergoing Staged Percutaneous Coronary Intervention　- A Subgroup Analysis of the STOPDAPT-3 Trial. (PubMed, Circ Rep) - "The no-aspirin group compared with the DAPT group had a numerically higher incidence of the co-primary cardiovascular endpoint, which occurred after the first staged PCI procedure (2.49% vs. 1.21%; HR 2.07; 95% CI 0.71-6.05). An aspirin-free prasugrel monotherapy relative to DAPT had numerically higher risks of cardiovascular and major bleeding events in patients undergoing staged PCI at 1 month."

Journal • Acute Coronary Syndrome • Cardiovascular • Hematological Disorders • Myocardial Infarction • Thrombosis

Antiplatelet versus anticoagulation treatment for people with heart failure in sinus rhythm. (PubMed, Cochrane Database Syst Rev) - "There is some evidence from RCTs that OAC with warfarin compared to platelet inhibition with aspirin probably has little to no effect on mortality in people with systolic heart failure in sinus rhythm (moderate-certainty evidence). Treatment with warfarin probably reduces non-fatal cardiovascular events but probably increases the risk of major bleeding complications (moderate-certainty evidence). We saw a similar pattern of results for the warfarin versus clopidogrel comparison (low-certainty evidence). At present, there are no data on the role of OAC versus antiplatelet agents in heart failure with preserved ejection fraction in sinus rhythm. Also, there were no data from RCTs on the utility of non-vitamin K antagonist oral anticoagulants compared to antiplatelet agents in heart failure with sinus rhythm."

Clinical • Journal • Review • Atrial Fibrillation • Cardiovascular • Congestive Heart Failure • Coronary Artery Disease • Heart Failure • Myocardial Infarction • Pulmonary Embolism • Respiratory Diseases

POLY-ACS: Polypill in Acute Coronary Syndrome (clinicaltrials.gov) - P2 | N=140 | Completed | Sponsor: University of Texas Southwestern Medical Center | Recruiting ➔ Completed

Trial completion • Acute Coronary Syndrome • Cardiovascular • Coronary Artery Disease

Comparative study of safety of cuffed tunnelled catheter on patients on dual anti-platelets compared with standard indications. (ERA 2025) - "The DAPT used were Ticagrelor( n =71), or Prasugrel ( n=32) or Clopidogrel( n=19) along with Ecosprin 75 mg depending on HAS-BLED score and feasibility. There was no difference in TCC complications in patients on DAPT compared to standard indications. This encourages the interventional nephrologist and cardiologists for TCC in patients with high risk of bleeding, especially in non-resolving AKI of cardio renal syndromes."

Clinical • Cardiovascular • Nephrology

Efficacy and safety of low-dose prasugrel as dual antiplatelet therapy in patients with ischemic heart disease: a systematic review and network meta-analysis of randomized controlled trials. (PubMed, Cardiovasc Interv Ther) - "The surface under the cumulative ranking curves was highest for low-dose prasugrel for both MACE and bleeding events (17.3 and 64.6 for clopidogrel, 84.5 and 84.9 for low-dose prasugrel, 62.0 and 11.8 for standard-dose prasugrel, and 36.2 and 38.7 for ticagrelor, respectively). Low-dose prasugrel may be a viable option in addition to standard P2Y12 receptor inhibitors."

Journal • Retrospective data • Cardiovascular • Coronary Artery Disease • Heart Failure • Myocardial Infarction

EValuation of Acute and Early Phase P2Y12 Inhibitor DE-escalation After PerCutaneous Intervention (EVADE PCI). (PubMed, Kans J Med) - "Aspirin and an oral P2Y12 inhibitor are recommended for one year after percutaneous coronary intervention (PCI) in patients with acute coronary syndromes. A composite outcome of all-cause mortality, urgent revascularization, stent thrombosis, stroke, and major bleeding at one year was similar between patients who continued ticagrelor or prasugrel and those de-escalated to clopidogrel within 30 days of PCI. Larger studies are needed to confirm these findings and assess the optimal timing for therapy adjustments."

Journal • Acute Coronary Syndrome • Cardiovascular • Hematological Disorders • Thrombosis

INTRACEREBRAL BLEEDING UNDER DUAL ANTIPLATELETS AFTER EMERGENCY RECANALIZATION OF INTRACRANIAL AND EXTRACRANIAL LARGE ARTERY OCCLUSION (ESOC 2025) - "78 patients (35.8%) received early dual antiplatelet agents, i.e. during or timely after ET and before 24 h CT control (ticagrelor in 28, clopidogrel in 46, tirofibane in 3, prasugrel in 1). Clopidogrel/ticagrelor in addition to ASA starting during or timely after intracranial ET and extracranial (stent-protected) PTA in acute stroke patients with extra-intracranial tandem occlusion seems not to be associated with an increased cerebral bleeding risk."

Cardiovascular

INFLUENCE OF CYP2C19 ON DIFFERENT ANTIPLATELET STRATEGIES FOR SECONDARY PREVENTION OF MAJOR ISCHEMIC EVENTS: SYSTEMATIC REVIEW AND META-ANALYSIS (ESOC 2025) - "Clopidogrel was less effective than prasugrel for MACE occurrence (1.57 times higher, p-interaction=0.02) and ticagrelor (1.21 times higher, p-interaction=0.19) in CYP2C19 variant carriers. Clopidogrel's efficacy in patients with CYP2C19 LoF genotype and cardiovascular disease, minor stroke, or TIA remains inconclusive. However, the size and direction of the effect warrants further research into the role of LoF genotypes and cost-effectiveness of testing. Prasugrel may be a more beneficial alternative for CYP2C19 LoF carriers."

Retrospective data • Review • Cardiovascular • Ischemic stroke • CYP2C19

UNDERSTANDING RECURRENT STROKES IN A CASE OF BOW HUNTER SYNDROME WITH COMORBID ATRIAL FIBRILLATION: A CASE STUDY (ESOC 2025) - "Despite adding aspirin to her apixaban then switching this to prasugrel, the patient continued to experience strokes in the posterior circulation. This case highlights the difficulties in managing recurrent strokes related to BHS, particularly in patients receiving anticoagulation. This emphasises the need to consider rarer causes in addition to traditional risk factors and a nuanced multidisciplinary approach in addressing recurrent strokes associated with vascular anomalies."

Case study • Clinical • Atrial Fibrillation • Cardiovascular

Switching antiplatelet therapy based on P2Y12 reaction unit monitoring for recurrent acute thrombosis due to prasugrel resistance: A case report. (PubMed, J Cardiol Cases) - "Dual antiplatelet therapy including P2Y12 inhibitor is mandatory to prevent stent thrombosis in acute coronary syndrome and prasugrel is more frequently used in Japanese patients than clopidogrel due to its poor metabolizer profile...Although prasugrel resistance is rare and platelet function test is not common in daily practice, it is important to be familiar with alternative drugs for prasugrel resistance and how to suspect and treat these patients. Effects of antiplatelet therapy can be assessed by platelet function test (platelet aggregation test, VerifyNow, etc.).Although routine use of platelet function test has not been recommended, it might be useful in cases with repeated thrombotic events."

Journal • Acute Coronary Syndrome • Cardiovascular • Hematological Disorders • Thrombosis

Bleeding Complications of Anticoagulation Therapy Used in the Treatment of Acute Coronary Syndromes-Review of the Literature. (PubMed, J Clin Med) - "Pharmacological agents like aspirin, P2Y12 inhibitors (e.g., prasugrel, ticagrelor), glycoprotein IIb/IIIa inhibitors, and heparins are fundamental to ACS treatment but carry varying bleeding risks depending on individual patient profile...The findings underscore the importance of personalized antithrombotic regimens in ACS management, emphasizing precise risk assessment to enhance outcomes and mitigate adverse events. This review examines the mechanisms, risk factors, and strategies to mitigate bleeding associated with anticoagulant and antiplatelet therapies in ACS."

Journal • Review • Acute Coronary Syndrome • Cardiovascular